Longevity Biomedical (Longevity Biomedical) Cash-to-Debt : 0.00 (As of . 20)

View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Longevity Biomedical's cash to debt ratio for the quarter that ended in . 20 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Longevity Biomedical couldn't pay off its debt using the cash in hand for the quarter that ended in . 20.

The historical rank and industry rank for Longevity Biomedical's Cash-to-Debt or its related term are showing as below:

LBIO's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.485
* Ranked among companies with meaningful Cash-to-Debt only.

Longevity Biomedical Cash-to-Debt Historical Data

The historical data trend for Longevity Biomedical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Longevity Biomedical Cash-to-Debt Chart

Longevity Biomedical Annual Data

Trend

Cash-to-Debt

Longevity Biomedical Semi-Annual Data

Cash-to-Debt

Competitive Comparison of Longevity Biomedical's Cash-to-Debt

For the Biotechnology subindustry, Longevity Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Cash-to-Debt falls into.

Longevity Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Longevity Biomedical's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Longevity Biomedical's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Longevity Biomedical (NAS:LBIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Longevity Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011

Website

https://www.longevitybiomedical.com

Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines